News
Positron Emission Tomography (PET) and Computed Tomography (CT) are complementary imaging modalities that have revolutionised diagnostic and research strategies in modern medicine.
Positron Emission Tomography Market to grow at 5% CAGR driven by oncology and neurology uses by 2030
The global Positron Emission Tomography (PET) market is set to witness a growth rate of 5% in the next 5 years. Growing prevalence of chronic diseases; technological advancements in ...
Positron Emission Tomography (PET) Scanners Market Forecast USD 1,441.5 Million by 2025, Climbing to USD 2,415.9 Million by 2035 The positron emission tomography (PET) scanners market has gained ...
PET: Positron Emission Tomography, a nuclear imaging technique used to observe metabolic processes. CT: Computed Tomography, an imaging modality that uses x-rays to create detailed anatomical images.
Positron Emission Tomography (PET) Scanners Global Market Overview 2021-2023 & 2024-2030 - ResearchAndMarkets.com February 17, 2025 10:25 AM Eastern Standard Time ...
The article by LaCasce et al entitled “Positron Emission Tomography–Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance)” (J Clin Oncol 10.1200/JCO.22.00947) was ...
Reply to: Mid-Treatment Positron Emission Tomography–Adaptive Radiotherapy in Stage III Non–Small Cell Lung Cancer: Another Attempt Toward Personalized Care The following represents disclosure ...
Correspondence Staging of Non–Small-Cell Lung Cancer with Positron-Emission Tomography Published November 23, 2000 N Engl J Med 2000;343: 1571 - 1573 DOI: 10.1056/NEJM200011233432113 ...
PRESS RELEASE March 24, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has initiated the positron emission tomography (PET) ...
Jubilant Radiopharma Announces Investment of $50 million (USD) to Expand Positron Emission Tomography (PET) Manufacturing Network June 24, 2024 02:15 PM Eastern Daylight Time ...
SAN DIEGO, December 16, 2024--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results